A randomized, double-blind, placebo-controlied trial of subcutaneous etanercept (p75 souble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohns’ disease
This entry was posted in Uncategorized. Bookmark the permalink.